High Purity 99% Progesterone Acetate Megestrol MGA / CAS 595-33-5 for Acting Oral Contraceptives
Brief Introduction :
Product Name:Megestrol Acetate
CAS NO.: 595-33-5
Appearance: White or light yellow crystalline powder (methanol), odorless and tasteless. Melting point 214-216. Soluble in acetone, slightly soluble in ethanol, insoluble in water.
Megestrol acetate (INN, USAN, BAN, JAN; sold mainly under the brand names Megace and Megace ES), also known as 17α-acetoxy-6-dehydro-6-methylprogesterone, and sometimes abbreviated as MGA or MA, is a steroidal progestin and progesterone derivative (specifically, a 17-hydroxylated progesterone) with predominantly progestational and antigonadotropic effects.
Though sometimes referred to simply as megestrol, it is important to clarify that megestrol acetate is not the same as megestrol, which is a closely related but different compound.
Megestrol acetate is used mainly as an appetite stimulant in a variety of conditions and as an antineoplastic agent in the treatment of breast, endometrial, and prostate cancers. When given in relatively high doses, it can substantially increase appetite in most individuals, even those with advanced cancer, and is often used to boost appetite and induce weight gain in patients with cancer or HIV/AIDS-associated cachexia. It is also used as a contraceptive in combination with an estrogen at relatively low doses.
In addition to its use in humans, megestrol acetate has been used extensively in veterinary medicine in the treatment of medical conditions in cats and dogs.
Megestrol acetate is available as 5 mg, 20 mg and 40 mg tablets and in oral suspensions of 125 mg/ml and 40 mg/ml. It is used at a dose of 5 mg in combination with an estrogen for contraception. Appetite stimulation is achieved with doses ranging from 400 mg to 800 mg a day. Doses used to treat cancer usually range from 40 mg to 320 mg.
(1) Megestrol acetate tablets (2) Megestrol acetate dispersible tablets (3) Megestrol acetate capsules
Application: Palliative treatment for advanced breast and endometrial cancers
Tablet Breast Cancer 160mg/day, once or in divided doses. Endometrial cancer 40-320mg/day, once or in fractions. It is not recommended to apply within the first four months of pregnancy. Patients with a history of thrombophlebitis should be used with caution. Stop breastfeeding during treatment.